Cargando…
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
BACKGROUND: Vedolizumab, an anti-α(4)β(7) integrin approved for intravenous (IV) treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), was evaluated as a subcutaneous (SC) formulation in maintenance therapy for UC and CD in phase 3 VISIBLE 1, 2, and open-label...
Autores principales: | Sandborn, William J, Chen, Jingjing, Kisfalvi, Krisztina, Loftus, Edward V, D’Haens, Geert, Candela, Ninfa, Lasch, Karen, Wolf, Douglas C, Uddin, Sharif M, Danese, Silvio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449415/ https://www.ncbi.nlm.nih.gov/pubmed/37636008 http://dx.doi.org/10.1093/crocol/otad034 |
Ejemplares similares
-
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
por: Vermeire, Séverine, et al.
Publicado: (2021) -
The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017) -
Correction to: Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
Publicado: (2023) -
Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020) -
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study
por: Reinisch, Walter, et al.
Publicado: (2020)